JPH05194260A - ペプチド組成物 - Google Patents

ペプチド組成物

Info

Publication number
JPH05194260A
JPH05194260A JP4186621A JP18662192A JPH05194260A JP H05194260 A JPH05194260 A JP H05194260A JP 4186621 A JP4186621 A JP 4186621A JP 18662192 A JP18662192 A JP 18662192A JP H05194260 A JPH05194260 A JP H05194260A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
acid
lys
composition according
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4186621A
Other languages
English (en)
Japanese (ja)
Inventor
Azria Moise
ムワズ・アズリア
Gert Fricker
ゲルト・フリッカー
Jacky Vonderscher
ジャッキー・フォンデルシェール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919115202A external-priority patent/GB9115202D0/en
Priority claimed from GB929200748A external-priority patent/GB9200748D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPH05194260A publication Critical patent/JPH05194260A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP4186621A 1991-07-15 1992-07-14 ペプチド組成物 Pending JPH05194260A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919115202A GB9115202D0 (en) 1991-07-15 1991-07-15 Improvements relating to organic compounds
GB929200748A GB9200748D0 (en) 1992-01-14 1992-01-14 Improvements relating to organic compounds
GB9200748 1992-01-14
GB9115202 1992-01-14

Publications (1)

Publication Number Publication Date
JPH05194260A true JPH05194260A (ja) 1993-08-03

Family

ID=26299234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4186621A Pending JPH05194260A (ja) 1991-07-15 1992-07-14 ペプチド組成物

Country Status (7)

Country Link
JP (1) JPH05194260A (de)
BE (1) BE1007752A5 (de)
CH (1) CH685600A5 (de)
DE (1) DE4222647A1 (de)
FR (1) FR2682598B1 (de)
GB (1) GB2257908B (de)
IT (1) IT1263222B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228836B1 (en) 1997-04-14 2001-05-08 Mitsubishi-Tokyo Pharmaceuticals, Inc. Permucous preparation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698521A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Native calcitonin mimetics
US5698672A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
AU1808897A (en) * 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
GB9614235D0 (en) * 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151276A (en) * 1975-05-12 1979-04-24 Armour Pharmaceutical Company Method of suppressing gastric acid secretion by the oral administration of calcitonin
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
AU572815B2 (en) * 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
HU203204B (en) * 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
GB2218102B (en) * 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
DE69001991T2 (de) * 1989-11-16 1993-09-23 Phidea Spa Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228836B1 (en) 1997-04-14 2001-05-08 Mitsubishi-Tokyo Pharmaceuticals, Inc. Permucous preparation

Also Published As

Publication number Publication date
CH685600A5 (de) 1995-08-31
IT1263222B (it) 1996-08-05
DE4222647A1 (de) 1993-01-21
BE1007752A5 (fr) 1995-10-17
GB2257908A (en) 1993-01-27
ITRM920535A0 (it) 1992-07-14
GB9214830D0 (en) 1992-08-26
FR2682598A1 (fr) 1993-04-23
FR2682598B1 (fr) 1996-04-05
ITRM920535A1 (it) 1994-01-14
GB2257908B (en) 1995-12-20

Similar Documents

Publication Publication Date Title
US5578567A (en) Nasal pharmaceutical composition
RU2327484C2 (ru) Фармацевтическая композиция для назального всасывания
US5725852A (en) Transmucosal therapeutic composition
US5089482A (en) Pharmaceutical compositions for nasal administration containing steroid hormones and dimethyl-β-cyclodextrin
US5011678A (en) Composition and method for administration of pharmaceutically active substances
JP3549542B2 (ja) 経口用ペプチド薬剤
WO1997006813A1 (fr) Preparation pour muqueuses a base de peptides a activite physiologique
Lee et al. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer
JPH10114645A (ja) 経鼻投与用製剤
US5183802A (en) Pharmaceutical compositions for intranasal administration of calcitonin
JPH05508616A (ja) 治療用エアロゾル剤
JPH0768149B2 (ja) 鼻腔内投与用調製剤およびその製法
WO2000074736A9 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
EP1643970A2 (de) Zusammensetzungen und verfahren für die verbesserte schleimhautabgabe von wachstumshormon
JPH0228121A (ja) 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH05194260A (ja) ペプチド組成物
IL133176A (en) Pharmaceutical preparations containing peptides in a low solubility vessel in a physiological medium
EP0540631A1 (de) Transmucosal-wirkstoffzusammensetzung und transmucosal-verabreichung
JPH04230223A (ja) ソマトスタチン吸収改善医薬組成物、その製法および用途
WO1992016196A1 (en) A composition comprising a peptide for nasal administration
JPS62207226A (ja) 経鼻投与用製剤
IE83304B1 (en) Pharmaceutical compositions comprising calcitonin
JP3123100B2 (ja) 吸収促進剤
WO2021129779A1 (zh) 一种新型两亲性蛋白、其制备方法及用途
JPS63243033A (ja) 経鼻投与組成物